Trial aims to stop deadly gut infection in High-Risk patients
Disease control
Completed
This study tested if adding the drug bezlotoxumab to standard care could prevent severe outcomes in patients with a dangerous C. difficile gut infection. It focused on 44 patients identified as high-risk using a special score based on their genes, blood tests, and gut bacteria. T…
Phase: PHASE2 • Sponsor: Hellenic Institute for the Study of Sepsis • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC